Frequency of Hepatocellular Carcinoma in Cirrhotic Patients with Hepatitis C in Hyderabad Pakistan
Article Sidebar
Main Article Content
Abstract
Background: Hepatocellular carcinoma (HCC) is a primary liver malignancy predominantly found in patients with cirrhosis due to chronic hepatitis C virus (HCV) infection. Chronic HCV infection is a significant risk factor for the development of cirrhosis, which markedly increases the risk of HCC. This study aims to evaluate the frequency of hepatocellular carcinoma in cirrhotic patients with hepatitis C.
Objective: To evaluate the prevalence of hepatocellular carcinoma among cirrhotic patients with hepatitis C virus infection in Hyderabad, Pakistan.
Methods: This descriptive study was conducted at the Department of Gastroenterology, Asian Institute of Medical Sciences (AIMS), Hyderabad, from January 2024 to June 2024. The study included 152 patients diagnosed with liver cirrhosis due to HCV infection. Non-probability consecutive sampling was employed. Patients with cirrhosis due to other causes, such as hepatitis B virus, alcoholic liver disease, hemochromatosis, Wilson disease, and end-stage liver disease, were excluded. Upon admission, each patient underwent a thorough history and physical examination, followed by laboratory investigations including alpha-fetoprotein (AFP) levels and ultrasonography. An AFP level greater than 200 ng/mL in the presence of a liver mass was considered highly indicative of HCC, obviating the need for a biopsy. All laboratory tests were conducted at a single laboratory to ensure uniformity. Data analysis was performed using SPSS version 26.0. Frequencies and percentages were calculated for categorical variables, while means and standard deviations were computed for continuous variables. Statistical tests of significance were applied at a 5% significance level.
Results: Out of 152 patients, 103 (67.8%) were male and 49 (32.2%) were female, with a mean age of 41.57 ± 10.67 years. The prevalence of hepatocellular carcinoma was found to be 7.2% (11 patients). Significant differences were observed in several liver function parameters between HCC and non-HCC patients: total bilirubin (4.22 ± 0.76 mg/dL vs. 1.44 ± 1.14 mg/dL, p = 0.001), AST (37.82 ± 14.25 U/L vs. 12.39 ± 6.54 U/L, p = 0.001), GGT (171.8 ± 81.27 U/L vs. 54.43 ± 59.41 U/L, p = 0.001), AFP (323.6 ± 59.60 ng/mL vs. 15.50 ± 21.04 ng/mL, p = 0.001), and INR (2.75 ± 1.23 vs. 1.24 ± 0.42, p = 0.001).
Conclusion: A notable prevalence of hepatocellular carcinoma was observed in cirrhotic patients with hepatitis C. This finding underscores the importance of regular screening and surveillance for HCC in this high-risk population to enable early detection and timely intervention.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
Shim CW, Park JW, Kim SH, Kim JS, Kim BH, Kim SH, et al. Noncirrhotic Hepatocellular Carcinoma: Etiology and Occult Hepatitis B Virus Infection in a Hepatitis B Virus-Endemic Area. Therap Adv Gastroenterol. 2017;10(7):529-36.
Hafeez M, Nadeem M, Ahmed M. Hepatocellular Carcinoma (HCC), Where Do We Stand? Current Situation. Pak J Med Sci. 2020;36(3):344.
Ghouri YA, Mian I, Rowe JH. Review of Hepatocellular Carcinoma: Epidemiology, Etiology, and Carcinogenesis. J Carcinog. 2017;16.
Axley P, Ahmed Z, Ravi S, Singal AK. Hepatitis C Virus and Hepatocellular Carcinoma: A Narrative Review. J Clin Transl Hepatol. 2018;6(1):79.
Haqqi A, Munir R, Khalid M, Khurram M, Zaid M, Ali M, et al. Prevalence of Hepatitis C Virus Genotypes in Pakistan: Current Scenario and Review of Literature. Viral Immunol. 2019;32(9):402-13.
Abideen ZU, Siddique S, Nasrullah I, Khan JS, Rehman S, Tong Y, et al. A 2-Year Retrospective Study of Viral and Host-Associated Risk Factors in Pakistani Hepatocellular Carcinoma Patients. Eur J Gastroenterol Hepatol. 2019;31(9):1103-9.
Chu CY, Cheng CH, Chen HL, Lin IT, Wu CH, Lee YK, et al. Long-Term Histological Change in Chronic Hepatitis C Patients Who Had Received Peginterferon Plus Ribavirin Therapy with Sustained Virological Response. J Formos Med Assoc. 2019;118(7):1129-37.
Conti F, Buonfiglioli F, Scuteri A, Crespi C, Bolondi L, Caraceni P, et al. Early Occurrence and Recurrence of Hepatocellular Carcinoma in HCV-Related Cirrhosis Treated with Direct-Acting Antivirals. J Hepatol. 2016;65(4):727-33.
Huang G, Lau WY, Wang ZG, Pan ZY, Yuan SX, Shen F, Zhou WP, Wu MC. Antiviral Therapy Improves Postoperative Survival in Patients with Hepatocellular Carcinoma: A Randomized Controlled Trial. Ann Surg. 2015;261:56-66.
Kim TH, Kim SY, Tang A, Lee JM. Comparison of International Guidelines for Noninvasive Diagnosis of Hepatocellular Carcinoma: 2018 Update. Clin Mol Hepatol. 2019;25(3):245.
Yoo SH, Kwon JH, Nam SW, Kim HY, Kim CW, You CR, et al. Early Development of De Novo Hepatocellular Carcinoma After Direct‐Acting Agent Therapy: Comparison with Pegylated Interferon‐Based Therapy in Chronic Hepatitis C Patients. J Viral Hepat. 2018;25(10):1189-96.
Marrero JA, Kulik LM, Sirlin CB, Zhu AX, Finn RS, Abecassis MM, et al. Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology. 2018;68(2):723-50.
Sharaf AL, Elbadrawy EG, Abdellatif AM, Abd Al Monem N. Frequency of Hepatocellular Carcinoma in Cirrhotic Patients After Chronic Hepatitis C Infection Treatment with Direct-Acting Antivirals. Afro Egypt J Infect Endemic Dis. 2022;12(1):16-23.
Leung C, Yeoh SW, Patrick D, Ket S, Marion K, Gow P, et al. Characteristics of Hepatocellular Carcinoma in Cirrhotic and Non-Cirrhotic Non-Alcoholic Fatty Liver Disease. World J Gastroenterol. 2015;21(4):1189.
Muhi A, Ichikawa T, Motosugi U, Sano K, Fatima Z, Matsuda M, et al. Diffusion-Weighted Imaging of Hepatocellular Carcinoma for Predicting Early Recurrence and Survival After Hepatectomy. Hepatol Int. 2013;7:662-8.
Butt AS, Hamid S, Wadalawala AA, Ghufran M, Javed AA, Farooq O, et al. Hepatocellular Carcinoma in Native South Asian Pakistani Population; Trends, Clinico-Pathological Characteristics & Differences in Viral Marker Negative & Viral-Hepatocellular Carcinoma. BMC Res Notes. 2013;6:1-3.
Ogawa E, Furusyo N, Nomura H, Dohmen K, Higashi N, Takahashi K, Kawano A, Azuma K, Satoh T, Nakamuta M, Koyanagi T. Short‐Term Risk of Hepatocellular Carcinoma After Hepatitis C Virus Eradication Following Direct‐Acting Anti‐Viral Treatment. Aliment Pharmacol Ther. 2018;47(1):104-13.
Shin J, Yu JH, Jin YJ, Lee JW. Incidence and Clinical Features of Hepatitis C Virus-Associated Hepatocellular Carcinoma Patients Without Liver Cirrhosis in Hepatitis B Virus-Endemic Area. J Liver Cancer. 2021;21(1):34.
Tariq M, Ahad W, Tahir M, Ahmed A, Shafique HM. Frequency of Hepatocellular Carcinoma in Cirrhotic Patients with Hepatitis-C Virus Positive Patients in Karachi-Pakistan. Int J Res Med Sci. 2015;3(7):1594-8.
Irum N, Zakir M, Yousaf I, Farooq MY, Akhtar A, Mehmood S, et al. Frequency of Hepatocellular Carcinoma in Patients Infected with Hepatitis C Virus Visiting a Tertiary Care Hospital in Lahore for Computed Tomographic Evaluation. Adv Life Sci. 2022;9(2):214-8.